Results 101 to 110 of about 29,286 (231)
Dasatinib is considered an effective drug in imatinib-resistant chronic myeloid leukemia. Although reported to be well-tolerated, severe events such as pleural or pericardial effusion have been reported at 140 mg daily.
Maria-Theresa Krauth +5 more
doaj +1 more source
Dasatinib-Induced Chylothorax in Chronic Myeloid Leukemia
Pulmonary adverse events are common abnormalities associated with the use of dasatinib in chronic myeloid leukemia. We present a case of a 69-year-old man who suddenly developed a rare chylothorax pulmonary adverse event following 10 months of dasatinib ...
Baloch, Zulfiqar Zulfiqar Qutrio Baloch Qutrio +3 more
core +1 more source
This review systematically elucidates the multifactorial anti‐aging mechanisms of extracellular vesicles (EVs). By bridging fundamental biology with advanced bioengineering, scalable manufacturing, and clinical translation, it establishes a comprehensive framework for developing next‐generation EVs‐based precision nanotherapeutics to combat systemic ...
Xian Huang +6 more
wiley +1 more source
Abstract Background A drug designed for a specific target often interacts with multiple targets, either unintentionally or as part of its intended mechanism of action. This has been called pharmacological pleiotropy or polypharmacology. There are key endogenous ligands such as ATP, GABA and glutamate that act on various proteins in humans. Furthermore,
Hampus Ljunggren +8 more
wiley +1 more source
Análisis de costo-efectividad de dasatinib, comparado con nilotinib como tratamiento de segunda línea en pacientes diagnosticados con Leucemia Mieloide Crónica [PDF]
Objetivo: Evaluar la relación costo-efectividad de los tratamientos de segunda línea en pacientes diagnosticados de leucemia mieloide crónica (LMC), resistentes o intolerantes a imatinib, en fase crónica.
Quitián Reyes, David
core
BCPAP, SW1736, C643, Cal62 control (C), dasatinib-resistant (DR), and dasatinib-resistant cells maintained in 2μM dasatinib in response to indicated concentrations of selumetinib (μM) for 72 hours. Growth was measured by Sulforhodamine B.
Kelsey E. Wuensch (15074598) +11 more
core +1 more source
Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero +7 more
wiley +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Selenium‐Based Nanoplatforms: An Emerging Theranostic Paradigm for Gynecological Cancers
This reivew summarizes Selenium as a multifunctional anticancer regulator in gynecological cancers. It reduces tumor risk, enhances therapeutic efficacy, and reduces treatment toxicity. Selenium also overcomes chemoraditherapy resistance, improving overall treatment outcomes. ABSTRACT Gynecological cancers present significant therapeutic challenges due
Hejing Liu +9 more
wiley +1 more source
The main goal of this effort is to create an innovative electrochemical sensor for dasatinib detection in the presence of doxorubicin. It was possible to create Bi2WO6 nanosheets easily.
Mayada Hadi Al-qassi +2 more
doaj +1 more source

